Eli Lilly Unveils Promising Phase 3 Results for Omvoh in Children

Eli Lilly (LLY:NYSE) has partnered with Metis TechBio (7666.HK:HKSE) for up to $1.1B in a research deal on lipid nanoparticles, with most payments contingent on milestones. The upfront payment is in the low double-digit millions. Lilly's R&D spend was $14.6B over the last 12 months.

Eli Lilly (LLY) seeks pediatric approval for Omvoh after positive Phase 3 trial results. 50% of pediatric ulcerative colitis patients achieved remission at 52 weeks. The company's GF Value suggests a 20.4% undervaluation, with a GF Score of 96/100. Insiders sold $2.66B in shares over the past year, while 25 gurus hold positions, with 12 adding and 10 trimming.

Eli Lilly's Omvoh showed a 50% clinical remission rate in paediatric UC patients in the SHINE-2 study, meeting its primary endpoint. 81% achieved clinical response at week 12, and 73.1% maintained it at 52 weeks. Lilly plans to submit these data to global regulators for potential label expansion. Omvoh is already approved for adult UC and Crohn's disease.

Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.

Eli Lilly's experimental drug retatrutide, a triple hormone receptor agonist, showed significant weight loss in a Phase III trial. Participants with obesity and type 2 diabetes lost an average of 18.8% body weight over 80 weeks, with higher doses yielding even greater results. The drug targets GLP-1, GIP, and glucagon receptors, distinguishing it from competitors. FDA approval is anticipated next year.

Eli Lilly (LLY) plans to expand Omvoh's use for pediatric ulcerative colitis after a successful late-stage trial. The company aims to seek an indication extension for the therapy, which is currently approved for bowel disease. This follows a one-year study showing positive results in children with the inflammatory colon condition.